What was the market valuation of the US anti radiation-drugs market in 2024?

The market valuation was $916.44 Million in 2024. Read More

What is the projected market valuation for the US anti radiation-drugs market by 2035?

The projected valuation for 2035 is $2668.02 Million. Read More

What is the expected CAGR for the US anti radiation-drugs market during the forecast period 2025 - 2035?

The expected CAGR is 10.2% during the forecast period 2025 - 2035. Read More

Which companies are considered key players in the US anti radiation-drugs market?

Key players include Bristol-Myers Squibb, Merck & Co, Pfizer, Eli Lilly and Company, Novartis, Bayer AG, Sanofi, Amgen, and GSK. Read More

What are the main segments of the US anti radiation-drugs market?

The main segments include Compound, Application, and Distribution Channel. Read More

What was the valuation of Potassium Iodide (KI) in the Compound segment in 2024?

The valuation of Potassium Iodide (KI) was $183.29 Million in 2024. Read More

How much is the Cancer Treatment application projected to generate by 2035?

The Cancer Treatment application is projected to generate $600.0 Million by 2035. Read More

What is the expected valuation for Retail Pharmacies in the Distribution Channel segment by 2035?

The expected valuation for Retail Pharmacies is $1300.0 Million by 2035. Read More

What was the valuation of the Others category in the Compound segment in 2024?

The Others category in the Compound segment had a valuation of $458.22 Million in 2024. Read More

How does the market for Acute Radiation Syndrome (ARS) applications compare in 2024 and 2035?

The market for Acute Radiation Syndrome (ARS) applications was $100.0 Million in 2024 and is projected to reach $300.0 Million by 2035. Read More

US Anti Radiation Drugs Market

ID: MRFR/Pharma/17407-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

US Anti-Radiation Drugs Market Research Report By compound (Potassium lodide (Kl), Prussian Blue, DTPA (Diethylenetriamine Pentaacetate), Others), By application (Acute Radiation Syndrome (ARS), Cancer Treatment, Radiation Exposure, Others) and By distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) - Growth & Industry Forecast 2025 To 2035

US Anti Radiation Drugs Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Compound (USD Million)
  1. 4.1.1 Potassium lodide (Kl)
  2. 4.1.2 Prussian blue
  3. 4.1.3 DTPA (Diethylenetriamine Pentaacetate)
  4. 4.1.4 Others
2. 4.2 Construction, BY Application (USD Million)
  1. 4.2.1 Acute Radiation Syndrome (ARS)
  2. 4.2.2 Cancer Treatment
  3. 4.2.3 Radiation Exposure
  4. 4.2.4 Others
3. 4.3 Construction, BY Distribution Channel (USD Million)
  1. 4.3.1 Hospital Pharmacies
  2. 4.3.2 Retail Pharmacies
  3. 4.3.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol-Myers Squibb (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Eli Lilly and Company (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bayer AG (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Amgen (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 GSK (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY COMPOUND
3. 6.3 US MARKET ANALYSIS BY APPLICATION
4. 6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 KEY BUYING CRITERIA OF CONSTRUCTION
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF CONSTRUCTION
8. 6.8 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
9. 6.9 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 SUPPLY / VALUE CHAIN: CONSTRUCTION
11. 6.11 CONSTRUCTION, BY COMPOUND, 2024 (% SHARE)
12. 6.12 CONSTRUCTION, BY COMPOUND, 2024 TO 2035 (USD Million)
13. 6.13 CONSTRUCTION, BY APPLICATION, 2024 (% SHARE)
14. 6.14 CONSTRUCTION, BY APPLICATION, 2024 TO 2035 (USD Million)
15. 6.15 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
16. 6.16 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY COMPOUND, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Construction Market Segmentation

Construction By Compound (USD Million, 2025-2035)

Potassium lodide (Kl)
Prussian blue
DTPA (Diethylenetriamine Pentaacetate)
Others

Construction By Application (USD Million, 2025-2035)

Acute Radiation Syndrome (ARS)
Cancer Treatment
Radiation Exposure
Others

Construction By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”